Imagion Biosystems has lodged Pro-Rata Non-Renounceable Rights Issue: Notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth) with the Australian Securities Exchange.
View the Pro-Rata non-Renounceable Rights Issue announcement.
The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials
September 4, 2026
Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how the company is moving through the critical steps required